Recent advances in multidisciplinary therapy for sinonasal cancers
Liu Qian, Luo Jingwei
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Abstract:Sinonasal cancers (SNCs) are rare and heterogeneous diseases. Most patients present with locally advanced stage due to the insidious symptoms. In the majority of cases, the treatment strategy relies on the combination of surgery and radiotherapy, supplemented with or without chemotherapy. However, postoperative organ preserving rate is low, quality of life and clinical prognosis are poor. With recent advancement of surgical techniques, radiotherapy and chemotherapy techniques, certain progress has been reached in the diagnosis and treatment of SNCs. Nevertheless, the specific treatment regimen remains controversial. In this article, advances and controversies in SNC were reviewed.
Liu Qian,Luo Jingwei. Recent advances in multidisciplinary therapy for sinonasal cancers[J]. Chinese Journal of Radiation Oncology, 2022, 31(12): 1164-1167.
[1] Youlden DR, Cramb SM, Peters S, et al.International comparisons of the incidence and mortality of sinonasal cancer[J]. Cancer Epidemiol, 2013,37(6):770-779. DOI: 10.1016/j.canep.2013. 09.014. [2] Dutta R, Dubal PM, Svider PF, et al.Sinonasal malignancies: a population-based analysis of site-specific incidence and survival[J]. Laryngoscope, 2015,125(11):2491-2497. DOI: 10.1002/lary.25465. [3] Binazzi A, Ferrante P, Marinaccio A.Occupational exposure and sinonasal cancer: a systematic review and meta-analysis[J]. BMC Cancer, 2015,15:49. DOI: 10.1186/s12885-015-1042-2. [4] Ding R, Sun Q, Wang Y.Association between human papilloma virus infection and malignant sinonasal inverted papilloma[J]. Laryngoscope, 2021,131(6):1200-1205. DOI: 10.1002/lary.29125. [5] Chen CC, Yang SF.Human papillomavirus-related carcinoma with adenoid cystic-like features of the sinonasal tract (also known as human papillomavirus-related multiphenotypic sinonasal carcinoma)[J]. Arch Pathol Lab Med, 2019,143(11):1420-1424. DOI: 10.5858/arpa.2018-0027-RS. [6] Nukpook T, Ekalaksananan T, Teeramatwanich W, et al.Prevalence and association of Epstein-Barr virus infection with sinonasal inverted papilloma and sinonasal squamous cell carcinoma in the northeastern Thai population[J]. Infect Agent Cancer, 2020,15:43. DOI: 10.1186/s13027- 020-00308-5. [7] Torabi SJ, Spock T, Cardoso B, et al.Margins in sinonasal squamous cell carcinoma: predictors, outcomes, and the endoscopic approach[J]. Laryngoscope, 2020,130(6):E388-E396. DOI: 10.1002/lary.28315. [8] Ganly I, Patel SG, Singh B, et al.Complications of craniofacial resection for malignant tumors of the skull base: report of an international collaborative study[J]. Head Neck, 2005,27(6):445-451. DOI: 10.1002/hed.20166. [9] Lu VM, Ravindran K, Phan K, et al.Surgical outcomes of endoscopic versus open resection for primary sinonasal malignancy: a meta-analysis[J]. Am J Rhinol Allergy, 2019,33(5):608-616. DOI: 10.1177/1945892419856976. [10] Hagemann J, Roesner J, Helling S, et al.Long-term outcome for open and endoscopically resected sinonasal tumors[J]. Otolaryngol Head Neck Surg, 2019,160(5):862-869. DOI: 10.1177/0194599818815881. [11] Farquhar D, Kim L, Worrall D, et al.Propensity score analysis of endoscopic and open approaches to malignant paranasal and anterior skull base tumor outcomes[J]. Laryngoscope, 2016,126(8):1724-1729. DOI: 10.1002/lary.25885. [12] Abdelmeguid AS, Raza SM, Su SY, et al.Endoscopic resection of sinonasal malignancies[J]. Head Neck, 2020,42(4):645-652. DOI: 10.1002/hed.26047. [13] Xiao R, Joshi RR, Husain Q, et al.Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: effect of surgical approach[J]. Head Neck, 2019,41(10):3551-3563. DOI: 10.1002/hed.25873. [14] Lund VJ, Clarke PM, Swift AC, et al.Nose and paranasal sinus tumours: United Kingdom national multidisciplinary guidelines[J]. J Laryngol Otol, 2016,130(S2):S111-S118. DOI: 10.1017/S0022215116000530. [15] Iyer NG, Tan DS, Tan VK, et al.Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis[J]. Cancer, 2015,121(10):1599-1607. DOI: 10.1002/cncr.29251. [16] Jesse RH.Preoperative versus postoperative radiation in the treatment of squamous carcinoma of the paranasal sinuses[J]. Am J Surg, 1965,110(4):552-556. DOI: 10.1016/0002-9610(65)90036-x. [17] Liang ZG, Kusumawidjaja G, Kazmi F, et al.Intensity-modulated radiotherapy for paranasal sinuses and base of skull tumors[J]. Oral Oncol, 2018,86:61-68. DOI: 10.1016/j.oraloncology.2018.09.010. [18] Hu YH, Tu GY, Qi YQ, et al.Comparison of pre- and postoperative radiation in the combined treatment of carcinoma of maxillary sinus[J]. Int J Radiat Oncol Biol Phys, 1982,8(6):1045-1049. [19] Marcial VA, Gelber R, Kramer S, et al. Does preoperative irradiation increase the rate of surgical complications in carcinoma of the head and neck? A radiation therapy oncology group report[J]. Cancer, 1982,49(6):1297-1301. DOI: 10.1002/1097- 0142(19820315)49:6<1297::aid-cncr2820490637>3.0.co;2-j. [20] Guntinas-Lichius O, Kreppel MP, Stuetzer H, et al.Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients[J]. Eur J Surg Oncol, 2007,33(2):222-228. DOI: 10.1016/j.ejso.2006.10.033. [21] Wang Z, Qu Y, Wang K, et al.The value of preoperative radiotherapy in the treatment of locally advanced nasal cavity and paranasal sinus squamous cell carcinoma: a single institutional experience[J]. Oral Oncol, 2020,101:104512. DOI: 10.1016/j.oraloncology.2019.104512. [22] Chi A, Nguyen NP, Tse W, et al.Intensity modulated radiotherapy for sinonasal malignancies with a focus on optic pathway preservation[J]. J Hematol Oncol, 2013,6:4. DOI: 10.1186/1756-8722-6-4. [23] Frederic-Moreau T, Piram L, Bellini R, et al.Postoperative volumetric modulated arc therapy for sinonasal cancer: Improved survival compared with 3D conformal radiation therapy[J]. Head Neck, 2019,41(2):448-455. DOI: 10.1002/hed.25410. [24] Patel SH, Wang Z, Wong WW, et al.Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis[J]. Lancet Oncol, 2014,15(9):1027-1038. DOI: 10.1016/S1470-2045(14)70268-2. [25] Zhang W, Hu W, Hu J, et al.Carbon ion radiation therapy for sinonasal malignancies: promising results from 2282 cases from the real world[J]. Cancer Sci, 2020,111(12):4465-4479. DOI: 10.1111/cas.14650. [26] Jensen AD, Poulakis M, Nikoghosyan AV, et al.High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years' experience with raster-scanned carbon ion therapy[J]. Radiother Oncol, 2016,118(2):272-280. DOI: 10.1016/j.radonc.2015.05.010. [27] Abdelmeguid AS, Teeramatwanich W, Roberts DB, et al.Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses[J]. Cancer, 2021,127(11):1788-1795. DOI: 10.1002/cncr.33452. [28] Khoury T, Jang D, Carrau R, et al.Role of induction chemotherapy in sinonasal malignancies: a systematic review[J]. Int Forum Allergy Rhinol, 2019,9(2):212-219. DOI: 10.1002/alr.22229. [29] Turri-Zanoni M, Lambertoni A, Margherini S, et al.Multidisciplinary treatment algorithm for the management of sinonasal cancers with orbital invasion: a retrospective study[J]. Head Neck, 2019,41(8):2777-2788. DOI: 10.1002/hed.25759. [30] Amit M, Abdelmeguid AS, Watcherporn T, et al.Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma[J]. J Clin Oncol, 2019,37(6):504-512. DOI: 10.1200/JCO.18.00353. [31] Robin TP, Jones BL, Gordon OM, et al.A comprehensive comparative analysis of treatment modalities for sinonasal malignancies[J]. Cancer, 2017,123(16):3040-3049. DOI: 10.1002/cncr.30686. [32] Kang JH, Cho SH, Kim JP, et al.Treatment outcomes between concurrent chemoradiotherapy and combination of surgery, radiotherapy, and/or chemotherapy in stage III and IV maxillary sinus cancer: multi-institutional retrospective analysis[J]. J Oral Maxillofac Surg, 2012,70(7):1717-1723. DOI: 10.1016/j.joms.2011.06.221. [33] Kim JH, Lee YS, Chung YS, et al.Treatment outcomes of concurrent chemoradiotherapy for locally advanced sinonasal squamous cell carcinoma: a single-institution study[J]. Acta Otolaryngol, 2015,135(11):1189-1195. DOI: 10.3109/00016489.2015.1061697. [34] Homma A, Sakashita T, Yoshida D, et al.Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer[J]. Br J Cancer, 2013,109(12):2980-2986. DOI: 10.1038/bjc.2013.663. [35] Homma A, Onimaru R, Matsuura K, et al.Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (Japan Clinical Oncology Group 1212): Dose-finding phase[J]. Head Neck, 2018,40(3):475-484. DOI: 10.1002/hed.25001. [36] Llorente JL, López F, Suárez C, et al.Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances[J]. Nat Rev Clin Oncol, 2014,11(8):460-472. DOI: 10.1038/nrclinonc.2014.97. [37] Riobello C, Vivanco B, Reda S, et al.Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer[J]. Head Neck, 2018,40(4):818-827. DOI: 10.1002/hed.25067. [38] Hongo T, Yamamoto H, Jiromaru R, et al.PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma[J]. Mod Pathol, 2021,34(11):1966-1978. DOI: 10.1038/s41379-021-00868-w.